BARACLUDE, (entecavir), antiviral for hepatitis B
INFCTIOUS DISEASES - Update
Opinions on drugs -
Posted on
Nov 03 2016
Reason for request
Extension of indication
- BARACLUDE now has Marketing Authorisation in the treatment of chronic hepatitis B virus (HBV) infections in nucleoside-treatment-naïve patients aged from 2 years to under 18 years, presenting compensated liver disease with evidence of active viral replication and persistently elevated serum ALAT levels, or histological evidence of moderate to severe hepatic inflammation and/or fibrosis.
- Like VIREAD, it represents a minor improvement in the treatment of these children.
Clinical Benefit
Substantial |
- |
Clinical Added Value
minor |
- |
English version
Contact Us
Évaluation des médicaments